Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2
Scott D. Bembenek,
Hariharan Venkatesan,
Hillary M. Peltier,
Mark D. Rosen,
Terrance D. Barrett,
Kimon C. Kanelakis,
Heather L. Palomino,
Theresa I. Brondstetter,
Taraneh Mirzadegan,
Michael H. Rabinowitz
Affiliations
Scott D. Bembenek
†Discovery Sciences, Janssen Research & Development, San Diego, California, United States
Hariharan Venkatesan
†Discovery Sciences, Janssen Research & Development, San Diego, California, United States
Hillary M. Peltier
Janssen Research & Development, San Diego, California, United States
Mark D. Rosen
Janssen Research & Development, San Diego, California, United States
Terrance D. Barrett
§Cardiovascular Metabolic Therapeutic Area, Janssen Research & Development, San Diego, California, United States
Kimon C. Kanelakis
Janssen Research & Development, San Diego, California, United States
Heather L. Palomino
Janssen Research & Development, San Diego, California, United States
Theresa I. Brondstetter
Janssen Research & Development, San Diego, California, United States
Taraneh Mirzadegan
†Discovery Sciences, Janssen Research & Development, San Diego, California, United States
Michael H. Rabinowitz
Janssen Research & Development, San Diego, California, United States
